On July 9, 2007 the Company issued a press release entitled Worlds First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland. The release stated that Northwest Biotherapeutics received an authorization for use from the Swiss authorities and that DCVax-Brain is the first commercially available therapeutic vaccine for such cancers. The Company intends to begin making the product available to patients in Q3 2007.

A week later, on July 16, 2007, Northwest Biotherapeutics issued another press release explaining that the authorization it received was really just for import/export purposes, and was conditional even for those limited purposes. Northwest Biotherapeutics stated that the Swiss government has not yet reviewed DCVax for neither safety nor efficacy. Northwest Biotherapeuticss stock which traded up from $2.30 per share to as high as over $7 per share during the Class Period has since dropped to below $3 per share.

To join the Northwest Biotherapeutics class action click on the link in the upper right corner of this page.